TABLE 1.
Baseline Characteristics
| HFpEFEAT− (n = 92) | HFpEFEAT+ (n = 77) | p Value | |
|---|---|---|---|
| Age, yrs | 66 ± 10 | 67 ± 12 | 0.48 |
| Female | 52 (57) | 52 (68) | 0.14 |
| Anthropometries | |||
| Height, cm | 167 ±9 | 168 ±10 | 0.37 |
| Ideal body weight, kg | 65 ± 12 | 63 ± 12 | 0.27 |
| Actual body weight, kg | 98 ± 15 | 112 ± 23 | <0.0001 |
| Body mass index, kg/m2 | 34.5 ± 4.2 | 39.9 ± 6.6 | <0.0001 |
| Comorbidities | |||
| Diabetes mellitus | 19 (21) | 23 (30) | 0.17 |
| Hypertension | 73 (79) | 65 (84) | 0.39 |
| Current atrial fibrillation | 16 (17) | 9 (25) | 0.24 |
| Medications | |||
| ACEI or ARB | 40 (43) | 35 (45) | 0.80 |
| Beta-blocker | 47 (51) | 43 (56) | 0.54 |
| Calcium-channel blocker | 17 (18) | 10 (13) | 0.35 |
| Loop diuretic | 42 (46) | 38 (49) | 0.63 |
| Laboratories | |||
| Hemoglobin, g/dl | 12.3 ± 1.7 | 12.2 ± 1.6 | 0.92 |
| eGFR, ml/min/1.73 m−2 | 63 ± 15 | 56 ± 20 | 0.02 |
| NT-proBNP, pg/ml | 719 ± 948 | 712 ± 956 | 0.97 |
Values are mean ± SD or n (%).
ACEI = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; EAT = epicardial adipose tissue; eGFR = estimated glomerular filtration rate; HFpEF = heart failure with preserved ejection fraction; HFpEFEAT+ = HFpEF with increased EAT; HFpEFEAT− = without increased EAT; NT-proBNP = N-terminal pro−B- type natriuretic peptide.